FDA Begins Safety Review of Mifepristone, Potential Restrictions Possible

The Food and Drug Administration has commenced a safety study concerning the abortion medication mifepristone. This review could potentially result in new limitations on the drug's availability, according to an FDA official. The agency's action carries significant implications for national health policy and reproductive healthcare access.